These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17459550)

  • 1. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 4. A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
    J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
    Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
    Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine.
    Munno D; Sterpone S; Fania S; Cappellin F; Mengozzi G; Saroldi M; Bechon E; Zullo G
    Panminerva Med; 2013 Dec; 55(4):377-84. PubMed ID: 24434345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients.
    Başterzi AD; Yazici K; Aslan E; Delialioğlu N; Taşdelen B; Tot Acar S; Yazici A
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):281-5. PubMed ID: 19110026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
    JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
    Shinkai K; Yoshimura R; Ueda N; Okamoto K; Nakamura J
    J Clin Psychopharmacol; 2004 Feb; 24(1):11-7. PubMed ID: 14709941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different serum BDNF levels in depression: results from BDNF studies in FYR Macedonia and Bulgaria.
    Ristevska-Dimitrovska G; Shishkov R; Gerazova VP; Vujovik V; Stefanovski B; Novotni A; Marinov P; Filov I
    Psychiatr Danub; 2013 Jun; 25(2):123-7. PubMed ID: 23793275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
    Kasper S; Pletan Y; Solles A; Tournoux A
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
    Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A; Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients.
    Yoshimura R; Kishi T; Suzuki A; Umene-Nakano W; Ikenouchi-Sugita A; Hori H; Otani K; Iwata N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1022-5. PubMed ID: 21338649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
    Chang TT; Lêng CH; Wu JY; Lee SY; Wang YS; Chen YC; Lu RB
    Chin J Physiol; 2008 Dec; 51(6):387-93. PubMed ID: 19280883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum BDNF levels before treatment predict SSRI response in depression.
    Wolkowitz OM; Wolf J; Shelly W; Rosser R; Burke HM; Lerner GK; Reus VI; Nelson JC; Epel ES; Mellon SH
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1623-30. PubMed ID: 21749907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment.
    Hellweg R; Ziegenhorn A; Heuser I; Deuschle M
    Pharmacopsychiatry; 2008 Mar; 41(2):66-71. PubMed ID: 18311687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of milnacipran: an overview.
    Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
    Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.